Last reviewed · How we verify
Fluvastatin extended release, fenofibrate — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Fluvastatin extended release, fenofibrate (Fluvastatin extended release, fenofibrate) — Novartis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fluvastatin extended release, fenofibrate TARGET | Fluvastatin extended release, fenofibrate | Novartis | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fluvastatin extended release, fenofibrate CI watch — RSS
- Fluvastatin extended release, fenofibrate CI watch — Atom
- Fluvastatin extended release, fenofibrate CI watch — JSON
- Fluvastatin extended release, fenofibrate alone — RSS
Cite this brief
Drug Landscape (2026). Fluvastatin extended release, fenofibrate — Competitive Intelligence Brief. https://druglandscape.com/ci/fluvastatin-extended-release-fenofibrate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab